[{"orgOrder":0,"company":"Kimera Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kimera\u00ae Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo\u00ae for Treatment of ARDS Secondary to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kimera\u00ae Labs Receives FDA Phase I\/IIa IND Approval For Its MSC Exosomes Human Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Kimera Labs
A single intravenous dose of an isolated, proprietary placental cell line derived, mesenchymal stem extracellular vesicles is being investigated for the treatment of COVID-19 symptoms in adults with mild to moderate illness.
Lead Product(s):
Placental Cell Derived Mesenchymal Stem Therapy
Kimera® Labs has filed an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes.
Lead Product(s):
Mesenchymal Stem Cell- Derived Exosomes